NEW DELHI: AstraZeneca Pharma India has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion from the Central Drugs Standard ...

AstraZeneca Pharma India gets CDSCO nod for durvalumab to treat LS-SCLC: Our Bureau, Bengaluru Monday, March 10, 2025, 15:30 Hrs [IST] AstraZeneca Pharma India, received a Central ...

With this approval, durvalumab can now be used for treating patients with limited-stage small cell lung cancer (LS-SCLC) ...

AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...

MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...

Astrazeneca Pharma India added 2.08% to Rs 6846.10 after the company has received permission from the Central Drugs Standard Control Organisation (CDSCO) to import for sale and distribution of ...

The approval by the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India is for import, for sale and distribution of Durvalumab solution for ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...